TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, today announced that its medical cannabis division, Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched

CannaPoints

, a new program designed to support patients through their medical cannabis journey.

Blair MacNeil, President, Tilray Canada, said, “We’re proud to expand our medical cannabis portfolio in Canada and broaden our offerings for our growing patient community. Our new CannaPoints program serves to guide our patients on their medical cannabis journey and provide additional support as needed.”

In Canada, Tilray Medical offers a broad portfolio of medical cannabis brands including Tilray, Aphria, Broken Coast, and Symbios. Understanding that patient needs are unique, Tilray Medical’s latest release of high-quality medical cannabis products from differentiated brands includes a comprehensive range of THC and CBD products:

Tilray:

• 
  Tilray Sinaloa Gold:
  
  A high THC sativa strain. Terpenes include d-Limonene, beta-Myrcene, and beta-Caryophyllene.
• 
  Tilray Sapphire Scout:
  
  A genetic blend of Girl Scout Cookies crossed with True OG. Terpenes include Limonene, Linalool, and Trans-Caryophyllene.
• 
  Tilray Chem Cookies:
  
  Chem Cookies is a result of two cannabis strains: Chemdawg #4 and Girl Scout Cookies (a.k.a. GSC). Terpenes include d-Limonene, beta-Myrcene, and beta-Caryophyllene.
• 
  Tilray Powdered Donuts #8:
  
  Powdered Donuts #8 is a high-THC strain. Terpenes include d-Limonene, beta-Myrcene, and beta-Caryophyllene.

Aphria:

• 
  Aphria Sherbet Cookies:
  
  Sherbet Cookies is a high THC hybrid strain. Terpenes include Humulene, Nerolidol and beta-Caryophyllene.
• 
  Aphria Banana Punch:
  
  Banana Punch is a high THC hybrid strain made from Banana OG and Purple Punch. Terpenes include limonene, pinene and beta-Caryophyllene.
• 
  Aphria Monkey Butter:
  
  Monkey Butter is another high THC hybrid strain made from the combination of Gorilla Glue #4 x Peanut Butter Breath. Terpenes also include: Humulene, Cedrene, and beta-Caryophyllene.
  

To further support the medical cannabis journey for patients, Tilray Medical partnered with

Strainprint

, a mobile app focused on medical cannabis tracking, to develop the

CannaPoints

program. Alongside advice from a physician, Tilray Medical patients can use the

CannaPoints

program to explore new offerings, learn more about strain details, and record the effects, making it easier for them to curate optimal personal consumption schedules, empowering them to tailor their own experiences and earn rewards through the app in the process. Patients can download the app for FREE, and kickstart their journey on the

App Store

, or

Google Play

for Apple and Android devices.

About Tilray Medical


Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.

For more information on Tilray Medical, visit


Tilray Medical Canada


and follow

@TilrayMedical

on Instagram.

About Tilray Brands


Tilray Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience of health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.

For more information on how we open a world of wellbeing, visit


www.Tilray.com


and follow @Tilray on all social platforms.

Forward-Looking Statements


Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

Contacts:

Tilray Global:


Kaitlin Macapagal

[email protected]

Investors


Raphael Gross

203-682-8253

[email protected]